Introduction
Efficient gene transfer into brain cells is a major goal for neurobiological studies and for the development of gene therapy for various human neurological diseases which currently have no effective treatment. Various gene delivery systems are available. 1 Replication-defective adenoviral vectors offer many advantages for gene transfer into the central nervous system, such as the ability to infect a wide variety of brain cells including post-mitotic neurons, high transduction efficiency and low pathogenicity. 2, 3 Moreover, adenoviral vectors have a cloning capacity of several kilobases and the adenoviral DNA does not integrate into the host genome, avoiding the mutagenesis risk associated with retroviral vectors. 1 Most gene delivery vectors use viral promoters, particularly the Rous sarcoma virus (RSV) or cytomegalovirus (CMV) promoters, because they have high transcription levels. They drive transgene expression in all infected cells whatever their type. The development of gene transfer strategies for the central nervous system requires the selective targeting of transgene expression to particular cells. The expression of genes encoding neurotrophic factors or substitutive enzymes should be restricted to spe-cific cell types, to limit the side-effects caused by the expression of such genes in healthy cells. Cell-specific promoters, which drive the expression of genes encoding tissue-or cell-specific proteins, could be used to target transgene transcription. Moreover, cell-specific promoters may give a level of expression better adapted to cellular metabolism, facilitating the longer-term expression of the transgene. Indeed, the short-term efficiency of viral promoters suggests the down-regulation of transcription, probably by cellular defense mechanisms. 1 Therefore, transgene expression could also be prolonged by improving transcriptional regulation.
Purkinje cell-and oligodendrocyte-specific promoters have been used in adenoviral vectors for specific cellular targeting. 4 In our study, we targeted neurons because they play a crucial role in the central nervous system and are the principal cells affected in many neurological diseases.
Neuron-specific enolase (NSE), an isoform of the glycolytic enzyme enolase, is one of the most abundant proteins in the adult mammalian brain, and is found in mature neurons and neuroendocrine cells. 5 Transient expression experiments have identified a region in the rat NSE promoter responsible for high-level expression in neuronal cells. 6 A 1.8 kb NSE promoter fragment has been shown to target the expression of various transgenes to differentiated neurons in transgenic animals. 7, 8 We constructed a first generation adenoviral vector containing the rat NSE promoter upstream from the LacZ reporter gene (Ad-NSE) and compared, in vitro and in vivo, the patterns of ␤-galactosidase gene expression from Ad-NSE and from an adenoviral vector containing the RSV promoter (Ad-RSV). Ad-NSE gave preferential expression of the transgene in brain neurons, with higher efficiency and lower toxicity than Ad-RSV. Ad-NSE also showed capacity of long-term expression.
Results
Neuron-specific expression of Ad-NSE The 1.8 kb NSE promoter, which has been shown to drive transgene expression in neurons in transgenic mice efficiently, was inserted into a transcriptional unit to control expression of the LacZ gene. Before generating the recombinant adenovirus, we first assessed the neuronspecific expression of the NSE-LacZ gene unit in the shuttle plasmids. The shuttle plasmids used to generate adenoviruses contain adenoviral sequences implicated in the partial dysregulation of some exogenous promoters. 9 We checked that these sequences did not affect the activity of the NSE promoter by comparing the ␤-galactosidase gene expression of pNSE with that of the shuttle plasmids, pAd-NSE and pAd-NSE(R), which contains the NSE-LacZ gene cassette in reverse orientation ( Figure 1 ). We found that adenoviral sequences did not affect the cell specificity or transcription rates of the adjacent NSE promoter (Figure 2a and b) . The three plasmids were similarly expressed in neuronal undifferentiated PC12 cells and restricted in non-neuronal 293 cells. The orientation of the transcriptional unit in the shuttle plasmid had no effect on ␤-galactosidase gene expression, based on comparisons between pAd-NSE and pAd-NSE(R). Therefore, the recombinant adenovirus Ad-NSE was arbitrarily constructed with the NSE-LacZ cassette in direct orientation.
␤-Galactosidase expression from Ad-NSE was compared in vitro with that from Ad-RSV following the infection of neuronal and non-neuronal cells. Ad-NSE was shown to give neuron-specific expression. ␤-Galactosidase was not expressed in non-neuronal HeLa cells, as shown by the 1:1000 ratio between the levels of expression from Ad-NSE and Ad-RSV (Figure 2e ). In the non-neuronal 293 cells, this ratio was 1:190 (Figure 2d ). In the NGF-differentiated neuronal PC12 cells (Figure  2g ), the undifferentiated PC12 cells (Figure 2f ) and the neuronal CHP 212 cells (Figure 2h ), the ratios were 1:2, 1:4 and 1:6, respectively. In rat primary cultures of sympathetic neurons ( Figure 2i ) and striatal neurons ( Figure  2c ), the ratios were 1:10 and 1:29, respectively. Linear dose-response curves were obtained for both adenoviruses ( Figure 2c ).
The adenoviruses were injected into the hippocampus, cerebellum and striatum of adult rats. In the hippocampal dentate gyrus, the patterns of expression of Ad-NSE and Ad-RSV were very different. The Ad-RSV-expressing cells had a diffuse anatomical distribution spread out from the neural cell layers (Figure 3b ), corresponding to the staining of neurons and astrocytes. In the granular cell layer, there were many stained nuclei on the inner side, where the astrocytes had their soma. Immunohistochemical analyses confirmed that these Ad-RSV-stained cells colocalized with the glial fibrillary acidic protein (GFAP) marker (Figure 3h) , and with the neuron-specific nuclear protein (NeuN) marker (Figure 3e ). Quantitative analysis showed that ␤-galactosidase was similarly expressed in both cell types after Ad-RSV infection ( Figure 4 ). In contrast, the Ad-NSE-expressing cells in the dentate gyrus were mostly in the granular neuronal cell layer ( Figure 3a) . Some interneurons and cells in the CA3 and CA4 pyramidal cell layers were also stained. Immunohistochemical colocalization of the Ad-NSE-stained cells with the NeuN marker showed that these cells were neuronal ( Figure 3d ). Only a few X-gal-stained cells in the granular cell layer and in the hippocampal fissure were also stained for the GFAP marker ( Figure 3g) . Nevertheless, the intensity of X-gal nuclear staining in astrocytes was more pronounced following Ad-RSV infection and sometimes led to diffusion of the enzyme into the cytoplasm (Figure 3k ; arrow).
Quantitative analysis showed that more than 1000 cells were transduced by Ad-NSE per 30-m section of the 1 mm rostral-caudal segment of the hippocampus analyzed, and confirmed that neurons were preferentially stained by Ad-NSE (more than 70% versus less than 30% for non-neuronal cells) ( Figure 4 ). The patterns of expression of Ad-NSE and Ad-RSV observed 7 days after their injection into the hippocampus (Figure 3d and e) were unchanged 14 days (data not shown) and 3. months later (Figure 5e and f). A two-factor analysis of variance (ANOVA) was used to determine the 'virus' effect and the 'time' effect on the number of LacZ-expressing cells in the injected hippocampus. The analysis revealed a statistically significant difference in the number of LacZexpressing neurons between the Ad-NSE and Ad-RSV groups whatever the time (F(1,2) = 26.662; P = 0.0355). The number of stained neurons was two to four times greater for Ad-NSE than for Ad-RSV, at each time-point analyzed ( Figure 4 ). There was no such difference for the non-neuronal cells.
In the cerebellum, the Ad-RSV-stained cells had a diffuse distribution, whereas the Ad-NSE-stained cells were restricted to the neuronal layers, 7 days and 3. months after the injection (Figure 5a and b), as observed in the hippocampus. Immunostaining experiments with the NeuN marker confirmed that the LacZ-expressing cells following Ad-NSE injection were essentially neurons (Figure 6a ), whereas the proportion of LacZ-expressing neurons was lower following Ad-RSV injection ( Figure  6b ). In the striatum, the area around the dorso-ventral axis of the needle track was similarly stained by the two adenoviruses (Figure 5c and d) . Immunostaining experiments demonstrated that most of the LacZ-expressing cells following Ad-NSE injection were double-labelled by the NeuN marker (Figure 6c ), whereas the proportion of double-labelling following Ad-RSV injection was clearly lower (Figure 6d ). A few cells were labelled by both adenoviruses in the ipsilateral pars compacta substantia nigra, due to axonal retrograde transport (data not shown).
Low toxicity of Ad-NSE
The inflammatory response of the brain to adenoviral infection was assessed by neutral red counter-staining and GFAP immunostaining. Ad-NSE infection with less than 4 × 10 7 plaque-forming units (p.f.u.) caused a minor inflammatory reaction similar to that following PBS injection. In the hippocampus, the glial reaction to 1.4 × 10 7 p.f.u. of Ad-RSV was stronger than that for Ad-NSE (data not shown). Reactive astrocytes, detected by vimentine immunostaining were more numerous after Ad-RSV infection than after Ad-NSE infection (Figure 3j and k) . Neuronal loss in the hippocampus was used to assess the cytotoxicity of the adenoviral infections. The granular cell layer narrowed more strongly at the injection site after Ad-RSV infection (Figure 3b ; arrow) than after Ad-NSE infection (Figure 3a ), due to a loss of neurons. Similar findings were observed at 3. months (data not shown).
Long-term expression from Ad-NSE Expressions from Ad-NSE and Ad-RSV were evaluated by quantitative analysis of the stained cells after intrahippocampal injection at 7 days, 14 days and 3. months ( Figure 4) . No statistically significant decrease of the number of stained neurons was observed at these three time-points, whatever the virus, using a two-factor ANOVA (F(2,2) = 7.796; P = 0.1137). Similarly, the differences between the number of non-neuronal stained cells over time were not statistically significant (F(3,2) = 6.943; P = 0.1285).
The expression kinetics of Ad-NSE were evaluated in the hippocampus at various time-points for up to 6 months ( Figure 7 ). The total number of stained cells slowly decreased up to 3. months, and a few cells were still labelled 6 months after the injection (last time analyzed) (Figure 5g and h) . The intensity of staining of these cells was not changed. 
u. of Ad-RSV on the right side (b, e, h, k). Neurons were immunostained by the NeuN marker (a-f) and astrocytes by the GFAP marker (g-i). Most Ad-NSE-infected cells, whose nuclei are blue stained, were localized in the dentate gyrus granular cell layer, gl (a) and were colabelled by the nuclear neuron-specific NeuN marker (detected by immunoperoxidase) giving a dark nuclear staining (d). A few stained cells in the granular cell layer were also colabelled by the cytosolic glial GFAP marker (detected by nickel reinforced immunoperoxidase) (g; arrows). The Ad-RSVstained cells are neurons (e) and astrocytes, the soma of which lie on the inner side of the granular layer (h; arrows). Diffusion of the X-gal staining to the cytoplasm sometimes allows morphological identification of astrocytes (k; arrow). A narrowing of the granular cell layer was detected at the injection site of Ad-RSV (b; arrow). Glial reaction evaluated by vimentine immunostaining is weaker after Ad-NSE infection (j) than after Ad-RSV infection (k). Control images of uninfected and immunostained hippocampal sections for which a X-gal reaction was performed (c, f, i, l). Scale

Discussion
Improvements of current gene transfer strategies are based, among others, on the transcriptional regulation of the transgene. A recombinant adenovirus able to direct transgene expression to neurons may be a particularly useful vector for gene therapy in the central nervous system. In this study, we constructed an adenoviral vector carrying the cell-specific NSE promoter (Ad-NSE), and demonstrated the neuron-specific expression of the transgene in this vector, whereas the transgene in a vector carrying the viral RSV promoter was expressed in a ubiquitous manner. Ad-NSE was also low in toxicity and gave long-term expression.
The fact that the NSE promoter fragment has been found to give specific expression in neurons in transgenic mice, does not guarantee a similar expression pattern in an adenoviral vector. The E1A gene enhancer, included within the packaging sequence, has been implicated in the partial dysregulation of the rat albumin and mouse ␤-major globin promoters in an adenoviral vector. 9 Our 
u. of Ad-NSE (a, c, e) and Ad-RSV (b, d, f) on opposite sides of the same animal. The Ad-NSE-stained cells were mostly in the Purkinje cell layer, pl, and in the granular cell layer, gl, counterstained with neutral red (a) whereas the Ad-RSV-stained cells were mostly in the molecular cell layer, ml (b). Persistence of ␤-galactosidase expression in the rat hippocampus 6 months after Ad-NSE injection (g, h). Scale bar: 300 m (a-d), 100 m (e-h). CA3 and CA4, pyramidal cell layers.
transfection experiments demonstrated that the E1A gene enhancer did not disrupt the activity of the adjacent NSE promoter. In vitro studies with Ad-NSE showed that the NSE promoter in the adenoviral backbone did indeed give neuron-specific expression. The high level of expression obtained with Ad-NSE in NGF-differentiated PC12 cells demonstrates that a cellular promoter may be as efficient as a viral promoter in specific cells, and that the level of expression from Ad-NSE in neuronal cells may be related to the maturity of these cells. These results are in accordance with the expression of the NSE protein in the PC12 neuroendocrine cells 5 and with a higher content of endogenous NSE mRNA in NGF-differentiated PC12 as compared with this content in undifferentiated PC12 cells. 6 The neuronal cell-specificity of the Ad-NSE vector was confirmed by the staining observed in the rat hippocampus and cerebellum, in which neuronal cell layers are easy to recognize. Immunostaining experiments performed in the hippocampus demonstrated that more than 70% of the Ad-NSE-stained cells were neurons, whereas neurons accounted for only 50% of the Ad-RSV-stained cells. Moreover, the number of neurons expressing ␤-galactosidase in the hippocampal granular cell layer was three times higher on average after Ad-NSE infection than after Ad-RSV infection. The staining of more than a b c d
Figure 6 NeuN immunostaining and histochemical staining for ␤-galactosidase in the rat cerebellum (a, b) and the striatum (c, d) 1 week after infection with 1.4 × 10 7 p.f.u. of Ad-NSE (a, c) and Ad-RSV (b, d). In the cerebellum, the Ad-NSE-stained cells colocalize with the neurons of the granular cell layer, gl. In the striatum, more colabelling with neurons (arrows) were observed following Ad-NSE infection than following Ad-RSV infection. Scale bar: 50 m; ml, molecular cell layer.
Figure 7 Expression kinetics of the Ad-NSE-stained cells in the hippocampus. Values are means ± s.e.m. for the total number of cells per 30 m-thick section (n = 6 sections). Analysis was performed at 7 days, 2 weeks, 1. months, 3. months, 4. months and 6 months following the injection.
800 neurons per section in the hippocampus following injection of Ad-NSE is particularly striking in view of the small number of virus particles used (1.4 × 10 7 p.f.u.). These major in vivo results conflict with those in vitro, in which the ␤-galactosidase activity after Ad-NSE infection was lower than that with Ad-RSV. This difference may be due to the activity of the NSE promoter which is better adapted to mature brain neurons than to fetal striatal neurons, newborn sympathetic neurons or undifferentiated PC12 and CHP 212 cells, given the lower levels of endogenous expression of the NSE protein in these cells.
The weak non-neuronal expression observed after Ad-NSE infection may be due to the characteristics of the rat NSE promoter. Its cell-specific activity is due to neuronal enhancers driving the activity of a basal promoter, 6 the basal promoter having 'house-keeping gene' features, generally associated with ubiquitous expression. 10 This minimal activity should be detectable in vivo in some non-neuronal cells following overinfection. In vitro, the detection of an expression in the 293 non-neuronal cells after Ad-NSE infection was not observed after NSE-containing plasmids transfection. The high level of adenoviral replication allowed in these E1 gene-containing cells could explain this difference in ␤-galactosidase expression. Preferential, rather than specific, neuronal expression has previously been observed following rat brain injection with naked plasmids containing the NSELacZ cassette 11 or adeno-associated virus (AAV) vector containing the NSE-green fluorescent protein cassette. 12 Strict cell-specific expression of the LacZ gene from recombinant adenoviruses carrying Purkinje cell-or oligodendrocyte-specific promoters has also been reported. 4 However, in the absence of further immunohistochemical analysis, the possibility of non-specific expression cannot be excluded. Our results with Ad-NSE demonstrate for the first time, high level of transgene expression in the neurons of the hippocampus, cerebellum and striatum.
Another important finding was the low cytotoxicity of Ad-NSE. This may be due to the physiological level of transcription from the NSE promoter, which should avoid the exhaustion of the protein synthesis machinery of infected cells. The overaccumulation of ␤-galactosidase in the nucleus of Ad-RSV-infected cells is probably toxic. ␤-Galactosidase may also induce an immune response mediated by antigen-presenting proteins (MCH I and MCH II), which are only present on glial cells. 13 The targeting of ␤-galactosidase to neurons by Ad-NSE may have attenuated this immune response. Further analyses need to be performed to study the differences between the brain inflammation caused by both adenoviruses.
Finally, we found that Ad-NSE gave long-term expression of the transgene. Transgene expression was still stronger in neurons at 3. months with the NSE promoter than with the RSV promoter, and it remained detectable for 6 months. Cellular promoters may be less sensitive to inactivation than viral promoters, as observed with retroviral vectors.
14 Episomal adenoviral DNA may be diluted and lost during cell division in reactive astrocytes following local brain infection, but this cannot occur in neurons. Adenoviral vectors containing viral promoters have been shown to express the ␤-galactosidase gene for 2 months after their injection into the brain, despite a decline in the number of stained cells. 2, 3, 15 Our results showed that ␤-galactosidase expression following Ad-RSV infection persisted for up to 3. months.
The high-level expression obtained in neurons with the NSE promoter and the advantages of the adenoviral vector represent major progress in the development of improved vectors for gene therapy in the central nervous system. However, the NSE promoter has performed less well in some other vectors. Naked plasmids containing the NSE-LacZ cassette appeared less efficient when injected into rat brain 11 than Ad-NSE. Recombinant herpes simplex virus, which is naturally tropic for neurons, was found to express the NSE-LacZ cassette inefficiently in vivo due to the vector high toxicity and transcriptional dysregulation by adjacent viral regions. 16 The NSE promoter was also tested in an adeno-associated virus (AAV) vector. 12 However, our study with an adenoviral vector gave higher efficiency in terms of the number of granular and pyramidal neurons stained in the hippocampus. Moreover, the adenovirus has a larger cloning capacity than the AAV vector, rendering our system more attractive for future applications. 1 This study demonstrates that recombinant adenoviruses containing the NSE promoter are the vector of choice for highly efficient and long-term expression of transgenes in brain neurons. The improvements obtained with the use of the NSE promoter, coupled with new generations of adenoviral vectors in which unnecessary, 17 or all 18 viral genes are deleted to prevent viral protein production, have potential for use in human clinical trials. Most animal experiments investigating gene transfer with adenoviral vectors have used viral promoters to drive the transgenes. It would be of interest to test whether the neuronal targeting of therapeutic agents, such as trophic factors, anti-oxidative agents 19 or specific enzymes 20 improves their neuroprotective or restorative effects.
In conclusion, the NSE-adenoviral vector offers the possibility of transferring potentially therapeutic genes into neurons within brain areas affected by various neurodegenerative diseases, such as the hippocampus in Alzheimer's disease, the striatum and the substantia nigra in Parkinson's disease, and in other neurological disorders such as focal refractory epilepsy.
Materials and methods
Plasmid construction pNSE contains the 1.8-kb upstream sequence and the untranslated leader sequence of exon I from the rat NSE gene driving the E. coli LacZ gene. The reporter gene is inserted between the nuclear localizing signal and the polyadenylation signal from SV40. Le Bert (personal   communication) demonstrated the pan-neuronal expression of this plasmid in transgenic mice. pAd-RSV, a gift from M Perricaudet, contains the RSV LTR promoter driving the same reporter gene. 21 This transcriptional unit is inserted between the adenoviral packaging sequence and a viral sequence facilitating homologous recombination.
The SpeI/XbaI fragment of pNSE containing the NSE promoter-LacZ gene was inserted into pAd-RSV in place of the SpeI/SalI fragment containing the RSV promoterLacZ gene. Shuttle plasmids, pAd-NSE and pAd-NSE(R), in which the transcriptional unit was in the same (pAd-NSE) and reverse orientation (pAd-NSE(R)) to pAd-RSV, were isolated.
Recombinant adenovirus generation
The construction of Ad-RSV has been described elsewhere. 21 A similar method was used to obtain the recombinant (E1-, E3-deleted) adenovirus Ad-NSE. Homologous recombination between the XmnI-linearized pAd-NSE and the large ClaI fragment of adenovirus 5 variant DNA was achieved by cotransfection of the 293 cell line by the calcium phosphate-DNA precipitation method. Viral stocks were prepared by propagation of the viruses in 293 cells, which have the E1 gene integrated into their genome to transcomplement the adenoviral genes. Stocks were purified by ultracentrifugation through two successive CsCl gradients, and dialyzed on a Sephadex G25M (Pharmacia, Uppsala, Sweden) column. Titers of viral stocks were determined by measuring optical density 22 and were checked by the plaque assay method. Functional quantification of adenoviral stocks by gene transfer assay 23 in 293 cells demonstrated the absence of a wild-type virus and a similar bioactivity of both adenoviruses according to the same number of X-gal-stained plaques for equivalent dilution of Ad-NSE and Ad-RSV.
In vitro transfection with plasmids
The rat pheochromocytoma undifferentiated PC12 cells were grown in RPMI 1640 (Gibco, Life Technologies, Cergy-Pontoise, France) containing 15% fetal calf serum (FCS). The human embryonic kidney 293 cells were grown in MEM containing 10% FCS and 1% non-essential amino-acids. The cells were transfected by electroporation using a BioRad Gene Pulser (Ivry sur Seine, France) at 190 V and 960 F. One picomole of each plasmid tested was used, along with 0.5 g of a plasmid encoding luciferase. Two days after transfection, cells were placed in a lysis solution containing 25 mm trisphosphate pH 7.8, 1 mm dithiothreitol, 8 mm MgCl 2 , 1 mm EDTA, 1% Triton X-100. ␤-Galactosidase activity was determined by chemiluminescence assay (Clontech, Palo Alto, CA, USA) in a Lumat LB 9501 luminometer (Berthold, Wildbad, Germany). Luciferase activity was assessed by adding 0.08 mm luciferin and 0.1 mm ATP to 50 l of the lysate and determining luminescence. All the in vitro experiments were repeated at least twice.
In vitro infection with adenoviruses
The human cervix carcinoma HeLa cells and the human neuroblastoma CHP 212 cells were grown in DMEM (Gibco, Life Technologies) containing 10% FCS and in DMEM-F12 (Gibco, Life Technologies) containing 15% FCS, respectively. Differentiated PC12 cells were grown in DMEM containing 10% horse serum, 5% FCS, 50 ng/ml nerve growth factor-␤ (Sigma, St Quentin-Fallavier, France) and 1% non-essential amino acids for 10 days. Primary cultures of superior cervical ganglia and striatal neurons were obtained from 1-to 2-day-old Wistar rats (Iffa-Credo, L'Arbresle, France) and from E15 Sprague-Dawley rat embryos (Iffa-Credo) respectively, as described elsewhere.
19,24 Adenoviral infections were performed 8 days after plating.
␤-Galactosidase activity was determined 2 days after infection. Protein in the lysate was determined by the BioRad Laboratories' assay.
In vivo brain injection of adenoviruses Viral stocks were diluted to the appropriate concentration in PBS and one microliter of each dilution was slowly injected into the hippocampus (A: 4 mm, L: 2.5 mm, V: 7 mm), striatum (A: 8 mm, L: 3 mm, V: 6 mm) and cerebellum (A: −4.5 mm, L: 3 mm, V: 3.5 mm) of adult male Wistar rats (Iffa-Credo) according to the atlas of Albe-Fessard et al. 25 For the expression kinetics study, 1.4 × 10 7 p.f.u. of Ad-NSE were injected into the hippocampus, and ␤-galactosidase activity assayed from 7 days to 6 months (n = 6). This number of adenoviral particles was previously shown to give high efficiency and only a minor inflammatory response by testing the injection of various dilutions of the viral stock into the hippocampus (data not shown). Ad-NSE was compared with Ad-RSV by injecting 1.4 × 10 7 p.f.u. of Ad-NSE into the left side of the hippocampus, and striatum or cerebellum (n = 4). The same amount of Ad-RSV was injected contralaterally (n = 4). Animals were anaesthetized with sodium pentobarbital and were perfused intracardially with 4% paraformaldehyde. Brains were post-fixed for 2 h, cryoprotected by incubation for 2 days in 30% sucrose at 4°C, and sectioned (30 m thick sections) on a freezing microtome.
For ␤-galactosidase detection, sections were incubated for 1 h at 37°C with the chromogenic X-gal substrate (0.1%), in a solution containing 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, and 2 mm MgCl 2 .
Immunostaining of E. coli ␤-galactosidase with rabbit anti-␤-gal antibodies (1:800; Amersham, Les Ulis, France) on adjacent tissue sections confirmed the specificity obtained with the X-gal reaction (data not shown). For immunostaining, mouse anti-NeuN (1:500; Chemicon, Temecula, CA, USA), anti-vimentine (1:500; Dako, Trappes, France), or rabbit anti-GFAP (1:500; Dako) antibodies were used. The secondary antibodies were antirabbit antiserum (1:250) coupled to rabbit peroxidaseantiperoxidase for ␤-galactosidase and GFAP, and biotinylated anti-mouse IgG (1:250) coupled to streptavidinbiotinylated-peroxidase complex for NeuN and vimentine. Diaminobenzidine with H 2 O 2 was used to detect the secondary antibodies.
For in vivo quantitative analysis, the number of cells stained positively for X-gal was counted every five coronal sections along a 1 mm segment of the hippocampus. Ad-NSE (n = 4) and Ad-RSV (n = 4) were compared at 7 days (n = 1 per virus), 2 weeks (n = 1 per virus) and 3. months (n = 2 per virus) after injection. From two to four photographs were done at a high magnification for each analyzed hippocampal section. The number of X-gal cells that colocalized or not with the NeuN marker was assessed by manual counting on each hippocampal section on blind-coded prints.
